Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 LONDON, April 25, 2024 /PRNewswire/ .
Lantheus (NASDAQ:LNTH – Get Free Report) and Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Risk and Volatility Lantheus has a beta of […]
Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 44.8% from the January 31st total of 100,500 shares. Approximately 4.2% of the shares of the stock are sold short. […]
Dubai Science Park study backs local research in medicine zawya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zawya.com Daily Mail and Mail on Sunday newspapers.